Merit Medical Announces The Launch Of The SureCross® Support Catheter

Merit Medical is pleased to announce the launch of the Merit SureCross® Support Catheter. The SureCross is used to guide and support guide wires, traverse vasculature, facilitate guide wire exchanges, and deliver infusions of saline, contrast, and therapeutic agents. It is designed to give physicians trackability, pushability, and visibility when treating patients with difficult occlusions resulting from peripheral arterial disease (P.A.D.).


  • 40 cm distal hydrophilic coating for smooth tracking through tortuous anatomy
  • Maximum infusion pressure of 300 psi


  • Low profile seamless transition from catheter to guide wire for exceptional crossing support
  • Matches guide wire outer diameter (OD) within 0.001″ for added strength and pushability


  • Translucent shaft for improved visualization
  • 3 platinum marker bands to confirm positioning
  • Internal platinum distal marker band
  • 2 mm distance from tip to marker band for accuracy of tip location

Contact your Merit Sales Representative to evaluate the SureCross Support Catheter today.

Tami Anderson
Senior Product Manager

Updated Version of Merit Convert App now Available in the iPhone App Store

An updated version of Merit Medical’s popular iPhone Convert App was launched with the release of the iPhone 6 and IOS8. Merit Convert is a handy tool for anyone with measurement conversions including area, length, mass, temperature and volume. For those in the Medical Device industry, the app also contains an artificial aging calculator, flow and pressure conversions and needle gauge and French size charts. There’s also a handy work week calendar so you can quickly determine the week that you’ll start and finish projects.

The Merit Convert App Version 1.4 includes minor design updates and bug fixes. To update the App if it’s already on your iPhone or to download the App for the first time, please visit the App Store on your iPhone. If you enjoy using the App, please take a moment to rate it!

To learn more visit

Michelle Stevens
Merit OEM Senior Marketing Communications Manager


Treatment of Metastatic Spinal Lesions with a Navigational Bipolar Radiofrequency Ablation Device: A Multicenter Retrospective Study

Praveen R. Anchala, MD, Winston D. Irving, MD, Travis J. Hillen, MD, Michael V. Friedman, MD, Bassem A. Georgy, MD, Douglass, M. Coldwell, MD, PhD, Nam D. Tran, MD, PhD, Frank D. Vrionis MD, PhD, Allan Brook, MD, and Jack W. Jennings, MD, PhD

Article presented the reality of fast and lasting relief from painful metastatic lesions

Praveen study 1


The STAR Tumor Ablation System:

  • Was safely & effectively used in the treatment of metastatic spinal tumors
  • Allowed RFA treatment of previously untreatable lesions which resulted in reduction of pain that was not controlled with systemic or radiation therapy
  • In certain cases with posterior wall involvement, posterior extension of tumor was halted
  • Did not hinder or delay other therapies

Catheter Patency is Vital for Patients with End-Stage Renal Disease

Catheter patency is vital for the delivery of hemodialysis and effective, long-term vascular access for patients with end-stage renal disease. Tunneled catheter thrombosis, as a result of venous thrombosis or the formation of fibrin sheaths, is a leading cause of catheter failure. Thrombosis can occur when the distal tip of the catheter comes in contact with the vessel wall, which can lead to vessel wall injury and fibrin sheath formation. The tip designs of many available long-term hemodialysis catheters on the market today allow for the tip of the catheter to come in contact with the vessel wall.

The CentrosFLO represents an innovative approach to the design of long-term hemodialysis catheters. The self-centering, curved-tip catheter has a greater separation between the arterial and venous tips compared to a symmetric-tip catheter. Its design is intended to optimize catheter patency, and to reduce fibrin sheath formation, thrombosis and vessel wall occlusions. This unique tip design keeps the tips of the catheter centered in the vessel and away from the vessel wall reducing vessel wall trauma.

An independent retrospective study1 conducted by a vascular access center showed 94.7% patency in the CentrosFLO catheter versus the competitor’s catheter, which had a patency rate of only 75% at 3 months. For more information about the CentrosFLO Long-Term Hemodialysis catheter, visit the CentrosFLO product web page.

  1 Balamuthusamy S. Self-centering, split-tip catheter has better patency than symmetric-tip tunneled hemodialysis catheter: single-center retrospective analysis. Semin Dial. 2014 Jan 20. Epub 2014 Jan 20

ReSolve® Non-Locking Drainage Catheter’s Smooth Transitions Help with One-Step Technique for Drainage

We have heard from many customers that the ReSolve Non-Locking Drainage Catheter (RNL) is great when using the one-step (direct puncture, trocar) technique when placing these catheters. The smooth transitions of the RNL help to insert the catheter smoothly through tissue without buckling, accordioning, or peeling back during insertion. Some of the drainage procedures that use the one-step technique include: abscess, paracentesis, thoracentesis, nephrostomy, and cyst.

Additional features:

  • Maximized drainage with large drainage holes
  • Decreased friction during placement with the hydrophilic coating
  • Maintain catheter patency via flexible material

To learn more, check out the ReSolve® Locking and Non-Locking Drainage Catheters product webpage.

Richard Collard
Senior Product Manager
Merit Medical Systems, Inc.

PreludeEASE™ Hydrophilic Sheath Introducer Receives CE Mark

I’m pleased to announce that the PreludeEASE hydrophilic sheath introducer has received the CE mark and is now available for sale in Europe. The PreludeEASE hydrophilic sheath introducer has been designed with the performance you need to achieve radial access with ease.


  • Hydrophilic coating can help reduce the incidence of arterial spasm during radial procedures.1
  • Coated to the tip of the sheath to facilitate easy insertion and removal.
  • Excellent transitions from dilator to wire and from sheath to dilator for smooth and easy insertion that can enhance patient comfort.
  • 4F-7F and 7, 11, 16, and 23 cm lengths for a variety of patient sizes and clinical needs.
  • Custom kit options
    • Merit Advance angiographic needle known for its sharpness and now with a bevel indicator
    • Spring coil, stainless steel, and nitinol mandrel guide wire options

PreludeEASE hydrophilic sheath introducers are a great complement to our growing line of products designed to support radial access procedures from start to finish.

To learn how you can achieve radial access with ease, contact a Merit Medical Sales Representative.

Stephanie Poulsen
Senior Product Manager

PreludeEASE is not 510(k) cleared for sale in the United States.

Merit Medical EMEA Launches Website

MAASTRICHT, The Netherlands— Merit Medical EMEA today launched its new website,

The new website is a key component of the company’s vision to be the most customer-focused company in healthcare. The eye-catching, user-friendly site was built with Merit Medical’s customers in mind, prominently featuring the company’s diverse range of products. In addition, provides healthcare professionals the opportunity to share their first-hand experiences with Merit Medical’s products.

“To be the most customer-focused company in healthcare, we must listen to our customers and value their feedback,” said Justin Lampropoulos, Merit Medical EMEA’s Executive Vice President. “Our new website provides an easy way for our healthcare partners to tell us what they like and dislike about our products. Their input is invaluable to us to innovate and deliver high-quality products that triumph the toughest clinical challenges and improve lives.”

The new EMEA website also highlights the “Think Radial. Discover Merit.” and “Think Embolics. Discover Merit.” campaigns and their integrated product portfolios. Additional features include the ability to request a visit from a Merit Sales Rep, customer service phone numbers for the more than 16 countries within Merit Medical EMEA’s boundaries, and the company’s latest news and history.


Merit Medical Systems, Inc. (NASDAQ: MMSI), has been designing, manufacturing and marketing single-use medical devices for more than 25 years and serves client hospitals worldwide with a domestic and international sales force totaling approximately 200 individuals. Merit Medical Systems employs approximately 3,000 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Maastricht and Venlo, the Netherlands; Paris, France; Galway, Ireland; Beijing, China; and Rockland, Massachusetts.

Safeguard® Pressure Assisted Device: Trusted Femoral Performance Now Available for Radial Procedures

Many of our customers use the Safeguard Pressure Assisted Device for hemostasis following femoral access procedures because they trust its compression, convenience and comfort. Merit Medical now has the Safeguard Radial™ compression device that offers the same trusted compression after radial procedures.


  • The Safeguard Radial’s inflatable bulb focuses compression only where you want it
  • It’s easy to adjust air in the bulb (inflation or deflation) using a standard Luer lock syringe
  • Trusted Compression, Comfort & Convenience
  • Now Available For Your Radial Procedures
  • The base plate and the way the band wraps around the bulb provides stable positioning, not occlusion
  • You already know how important patent hemostasis is for a radial compression device and the Safeguard Radial allows you to achieve patent hemostasis with patient comfort as well


  • While your patients come in many sizes, Safeguard Radial comes in one size that will fit them all
  • Having one compression device can reduce your inventory, maximize your precious storage space, and streamline ordering
  • You can use any syringe because Safeguard Radial has a standard Luer lock
  • The inflatable bulb lets you take distal and proximal pulses easily
  • The visibility of the clear bulb window allows you to check for oozing


  • Just like the Safeguard femoral, Safeguard Radial has a soft textile band with no plastic edges and a low profile design

So if you have been using the Safeguard for hemostasis following your femoral procedures, you can trust the Safeguard Radial to provide the same comfortable, convenient performance for radial compression.

Schedule an evaluation of the Safeguard Radial

Stephanie Poulsen
Senior Product Manager

Merit Medical Opens New Office in Tsim Sha Tsui, Kowloon, Hong Kong

Merit Medical Systems is pleased to announce the grand opening of a new office in Tsim Sha Tsui, Kowloon, Hong Kong. Merit Asia has been operating in Hong Kong for three years, and this larger office will help support our growing business with distributors in Hong Kong, Taiwan, and South East Asia.Joe Wright, President of Merit Technology Group was on hand to help with the ribbon cutting ceremony on June 12. Also pictured are Leon Lam, Vice President-Asia and Jo Choi, Regional Business Director for Hong Kong, Taiwan, and Southeast Asia.
Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures in several disciplines including cardiology, radiology, nephrology, vascular surgery, electrophysiology, and endoscopy. Our broad product portfolio includes therapeutic products for dialysis, embolization of uterine fibroids and tumors, and strictures of the airway.
Merit Medical’s new Hong Kong address is:
Room 901B, 9/F, Empire Centre
68 Mody Road, Tsim Sha Tsui
Kowloon, Hong Kong
Phone: +852 2628 3612 Fax: +852 2628 3130
歡迎 and 祝你好運 !

Multi-Center Trial Shows Significant Pain Relief For Spine Cancer Patients Following Targeted Radiofrequency Ablation Treatment

SAN JOSE, Calif. – July 21, 2014 – DFINE®, Inc., a market leader in the minimally invasive treatment of spinal diseases, today announced the publication of a multi-center study in the July/August issue of Pain Physician Journal, the official peer-reviewed publication of the American Society of Interventional Pain Physicians (ASIPP). The study followed patients at five leading academic centers and found a significant decrease (p<0.01) in pain scores after Targeted Radiofrequency Ablation™ (t-RFA) with the STAR Tumor Ablation System™.The participating centers included Washington University School of Medicine, Moffitt Cancer Center, Montefiore Medical Center and the Albert Einstein College of Medicine, University of Louisville Hospital and the University of California, San Diego. Physicians treated 128 lesions (metastatic tumors) in 92 patients. The average pain score before the procedure was 7.51 out of 10. Within one week post-procedure, the average pain score was reduced to just 1.73. Researchers also noted no patient complications or injuries.

“More than 40 percent of patients at the highest enrolling institution in this study had previous radiation treatment with little to no relief of symptoms,” said Jack W. Jennings, M.D., Ph.D, Assistant Professor and Director of Musculoskeletal and Spine Interventions, Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis. “Our study showed significant and almost immediate reduction in pain and more than half of the patients also decreased their use of pain medication. The procedure also allowed us to treat tumors close to the spinal cord that we have not been able to treat in the past.”

The American Cancer Society estimates that in 2014 there will be more than 1.7 million new cancer cases diagnosed and 585,720 cancer deaths in the United States.1 Metastatic lesions in bone are common and have been seen in up to 80 percent of patients with cancer at the time of death,2 with spinal metastasis seen in approximately 50 percent of these patients.3

“For late-stage cancer patients, extreme back pain due to spinal tumors degrades quality of life; and until now, limited minimally invasive procedural options for immediate pain relief have been available,” said Nam D. Tran, M.D., and Ph.D., neurooncology surgeon at Moffitt Cancer Center. “This multi-center study validates t-RFA as a treatment option that provides rapid, lasting pain relief without the need to interrupt the patient’s primary cancer therapy.”

About STAR™ Tumor Ablation System

t-RFA with the STAR System does not treat cancer. It is cleared by the FDA for providing palliative treatment (e.g. pain relief) by ablation of metastatic malignant tumors in a vertebral body. For a complete list of indications, risks and contraindications, visit—SpineSTAR

Treatment of Metastatic Posterior Vertebral Body Osseous Tumors by Using a Targeted Bipolar Radiofrequency Ablation Device: Technical Note

Travis J. Hillen, MD, Praveen R. Anchala, MD, Michael V. Friedman, and Jack W. Jennings, MD, PhD. Hillen, et al., Radiology. 2014 June 13:131664, E-pub prior to print Pubmed ID: 24927327   This article presented how targeted Radiofrequency Ablation (t-RFA) with the STAR Tumor Ablation System can serve as a Minimally Invasive Solution to Safely and Effectively Treat Previously Inaccessible Spinal Lesions



The STAR Tumor Ablation System:

  • Provides access to tumors that are difficult to reach with conventional ablation systems
  • Allows for safe & controlled ablation of spinal tumors
  • Does not hinder or delay other therapies
  • May provide an alternate therapy for tumors that do not respond to chemotherapy or radiation therapy

ReSolve® Biliary Locking Drainage Catheter Receives CE Mark!


I am pleased to announce that the ReSolve® Biliary Locking Drainage Catheter has received the CE mark and is available for sale in Europe.

These catheters are indicated for drainage of bile within the biliary system. Often biliary systems need to be decompressed due to bile duct stones, extrahepatic, or intrahepatic tumors, and primary sclerosing cholangitis, among other reasons. In addition bile may also need to be diverted from a bile duct leak.

Biliary system lesions do not always occur in the same location in every patient. Because of this, Merit offers catheters with two different drainage hole configurations to accommodate patient anatomy and multiple disease locations.

Correct catheter positioning is important in these procedures. The catheter features a radiopaque marker band near the proximal shaft drainage hole, and non-radiopaque depth markers the entire length of the catheter to help with fast and accurate positioning.

Additional features:

  • Atraumatic pigtail
  • Smooth transitions
  • Large drainage holes
  • Hydrophilic coating
  • Kink resistance

To learn more, check out the  ReSolve® Biliary Locking Drainage Catheter product webpage.

Richard Collard
Senior Product Manager
Merit Medical Systems, Inc.

Merit Medical Hosts Medical Education Course on LV Implantation Techniques

Merit Medical hosted a course on LV Lead Implantation Techniques May 4-5. The course was conducted by Seth J. Worley, MD, Director of the Interventional Implant Program at Lancaster General Hospital in Lancaster, Pennsylvania. Dr. Worley is an internationally recognized expert and key opinion leader in the advancement of cardiac resynchronization therapy.

Dr. Worley presented unique approaches to LV lead implantation and techniques designed to help reduce procedure and fluoroscopy time, reduce lead failure rates, and improve lead location.1

In addition to the hands-on training with the unique tools and techniques, Dr. Worley also used the tools in two live cases in which he was able to demonstrate successfully this specialized approach. Each of the eight physicians on hand were able to learn interactively as he described each of the steps in the procedure to the audience through a live video feed and to the physicians who joined him in the procedure room.

When used together, the Worley Advanced System provides the tools and solutions needed to reduce implantation times, gain easier access to the target vessel, and improve chances for successful CRT implantation.1

Worley™ Advanced CSG

Worley™ Advanced LVI

Worley™ Vein Selector

For more information or to register for the next Worley training course, contact your local Merit Medical Sales Representative or visit

Nelson Gardner
Business Development Manager

1 Jackson KP, Hegland DD, Frazier-Mills C, Piccini JP, Koontz JI, Atwater BD, Daubert JP, Worley SJ. Impact of using a telescoping-support catheter system for left ventricular lead placement on implant success and procedure time of cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2013 May; 36(5):553-8.

DFINE Announces Commencement Of Clinical Study On Spinal Tumor Ablation With The STAR Tumor Ablation System

San Jose, Calif. and Magdeburg, Germany – June 11, 2014DFINE®, Inc., a market leader in the minimally invasive treatment of spinal diseases, today announced that the first patient has been enrolled in the EU-STAR Clinical Trial. The multi-center trial is the first prospective study to evaluate clinical outcomes in patients receiving treatment with the STAR™ Tumor Ablation System for the palliative treatment of metastatic spinal tumors.

DFINE will enroll 40 patients at five centers in Germany and France. The trial will evaluate pain relief at one month as a primary outcome measure with follow up through six months. Secondary outcome measures include change in function, quality of life and pain medications post-procedure.

“We’ve had very promising results with targeted RF ablation (t-RFA™) to ‘melt’ the tumor followed by RF targeted vertebral augmentation™ (RF-TVA) during the same procedure to repair the damaged vertebrae,” said Dr. Boris Joellenbeck, a principal investigator at The Otto-von-Guericke University Magdeburg in Germany, where the first patient was treated. “Immediately following the procedure, the patient had a significant reduction in pain and increased activity level. We are excited about the many potential benefits of this therapeutic approach for our patients.”

Cancer is a major public health problem throughout the world, with more than 3.4 million new diagnoses each year in Europe alone.1 When cancer is not found early, it can metastasize (spread) to other parts of the body. A spinal tumor is a growth of cells (mass) in or around the vertebra near the spinal cord. It is estimated that 30-40 percent of cancer patients will likely develop metastatic spinal tumors.Many of these tumors also result in fractures of the vertebrae.

“t-RFA and RF-TVA provide an innovative new treatment option for the many patients worldwide who suffer from the debilitating effects of spinal tumors,” said Greg Barrett, Chief Executive Officer of DFINE. “As a company we are committed to building a body of scientific evidence supporting the therapy and are excited to partner with several leading medical centers in Germany and France on this landmark trial.”

To learn more about the EU-STAR clinical trial (ID # NCT02081053), interested parties may contact the study research staff found here: 

About STAR™ Tumor Ablation System

t-RFA with the STAR System does not treat cancer. It is cleared by the FDA for providing palliative treatment (e.g. pain relief) by ablation of metastatic malignant tumors in a vertebral body. For a complete list of indications, risks and contraindications, visit—SpineSTAR

About DFINE, Inc.

DFINE is dedicated to relieving pain and improving the quality of life for patients suffering from spinal diseases through innovative, minimally invasive therapies. The company’s flagship products, the StabiliT® Vertebral Augmentation System and STAR™ Tumor Ablation System, represent generational advancements in the minimally invasive treatment of spinal diseases. DFINE is based in San Jose, Calif. and is a privately held company.

DFINE and StabiliT are registered trademarks and STAR and Targeted Radiofrequency Ablation (t-RFA) are trademarks of DFINE, Inc. [media-contact]

SCAI 2014 Attendees Get Hands On with Merit Medical’s Radial-Specific Products

Attendees were offered hands-on demonstrations of our radial products at the Society for Cardiovascular Angiography and Interventions (SCAI) meeting last week in Las Vegas. We exhibited several products supporting transradial access–the Rad Board® radial arm board and accessories, radial catheters, and the Safeguard Radial™ radial closure device–that generated lots of interest at the booth.

With dedicated, radial-specific arm boards and accessories, cath lab personnel don’t need to use towels to obtain correct arm positioning. The reusable Rad Board fits all cath lab and radiology procedure tables. Visitors at the booth were surprised to learn that there is a section of Xenolite TB embedded in the Rad Board that helps to reduce scatter radiation exposure. See Radiation Scatter Survey Results.

We had a vascular model that attendees could use for a hands-on demonstration of our Performa Ultimate™ line of catheters. Merit also has the MIV™ radial ventriculogram pigtail catheter that is designed to angle toward the left coronary cusp to facilitate transradial access.

We demonstrated the Safeguard Radial pressure assisted device by putting it on some attendees. As a result, they learned firsthand how comfortable and convenient it is to get adjustable compression of the radial puncture site.

Attendees at SCAI this year were excited to learn about Merit’s new Think Radial training courses and enjoyed the hands-on demonstrations of our radial-specific products. For more information on our radial product portfolio or upcoming training courses, Contact Us.

Chan Ream
Product Manager

Merit Medical To Exhibit at PICS-AICS 2014 Chicago Symposium

For 16 years, Merit Medical has participated as an exhibitor at the Pediatric and Adult Interventional Cardiac Symposium (PICS-AICS). This year, the symposium will be held at the Marriott Chicago Downtown, June 7-10, 2014.

Merit Medical is committed to supplying purpose-built pediatric products for diagnostic and interventional medicine, particularly for interventional cardiology.

  • The Merit Diagnostic Cardiology FEP Catheter line includes a 3F Pediatric Pigtail Catheter.
  • The Merit Pediatric Judkins Right and Judkins Left Catheters are available with shapes as small as JR 1.5 and JL 1.5.
  • Merit also provides Pediatric Vessel Sizing Catheters.

New to our pediatric product line this year are:

We would like to invite you to stop by Booth 311 to view these products and many others offered by Merit Medical for the Pediatric and Adult Interventional Cardiologist.

For more information about Merit’s pediatric products, Contact Us.

Tami Anderson
Senior Product Manager

Safeguard® and Ergonomics in the Cath Lab

I recently read an article by Marsha Holton, CCRN, RCIS, FSICP, “An Ergonomic Survey of Cath Lab Repetitive Stress Injuries,” who observed that the duration of manual compression may be one of the ergonomic risk factors for cath lab repetitive stress injuries.

“Survey results regarding recovering access sites were surprising, particularly the mean holding pressure time of 19 minutes*. We may have identified at least one task that could increase the risk of carpal tunnel injury to our health care workers. Three of the seven ergonomic risks are involved in holding manual pressure. These are the risks of position and pressure, force, and duration, which may explain the trembling of those hands that held for 19 minutes.” [* Emphasis added]

As a result of her survey, Ms. Holton encourages cath lab professionals to look for ways to reduce the risk of injury.

“If there is even a possibility that such injuries are caused by our work, it is important to identify what is hurting cath lab professionals, and what we can do to decrease the number of future injuries.”

For those who are looking for ways to reduce the duration of manual compression, I recommend using the Safeguard Pressure Assisted device. The Safeguard Manual Assist (SMAT) study—a multicenter trial of over 100 patients found that the device was effective in reducing active compression time.

  • The mean active compression time for all patients (n = 100): 7.7±3.3 minutes
  • The mean active compression time for diagnostic patients (n = 72): 6.6±2.9 minutes
  • The mean active compression time for interventional patients (n = 28): 10.5±2.5 minutes

Safeguard is indicated in the reduction of active compression time in femoral artery cannulation following diagnostic and interventional procedures and it is effective in obtaining and maintaining hemostasis. It has a clear polyurethane window and bladder with adhesive backing and a Luer valve for inflation with a syringe to provide pressure to the puncture site.

Testimonials from two of the nurses who participated in the SMAT study support the effectiveness and comfort of the device:

“Well, I love this product because my hand doesn’t hurt when I go home at night.” —Karen Cronin, RN

“Safeguard is just a great thing for nurses and a great thing for the patients.” —Judy Champion, RN

To learn more about the Safeguard Manual Assist Technique, contact your local Merit Medical Sales Representative.

Mark Heninger
Senior Product Manager

Merit Medical Offers PD Kit for Interventional Radiologists

Introducing the NEW Merit Percutaneous Implantation Kit for peritoneal dialysis (PD) catheter placement. The kit is designed to accommodate stylette or over-the-wire placement using ultrasound guided access and fluoroscopy. At the recent Society of Interventional Radiology (SIR) meeting in San Diego, physicians were thrilled to learn about this procedure and the advantages of the Merit percutaneous kit over the competitor’s kit. This percutaneous kit is unique because it has a number of components not currently offered in competitive kits. These unique features include:

  • 18G echogenic needle
  • Two Dilators: 12F and 14F for serial dilation
  • Cuff Implantor: Designed to simplify implanting the cuff through a smaller incision
  • 0.038″ x 150 cm Wire: Long enough to place the catheter over the wire
  • Tunneler: Specifically designed to match the O.D. of our catheter and sized for a small, tight exit site

Each Merit PD catheter, sold separately from the implantation kit, includes a sterile implantation stencil to promote placement accuracy and better PD catheter outcomes.

Product configurations: VP-511 (Includes plastic Faller Trocar) and VP-511M (Includes metal Faller Trocar)

In addition to these kits, Merit offers a number of interventional tools to assist in these procedures such as the Merit Laureate® hydrophilic guide wire and MAK-NV™ non-vascular micro puncture sets.

To learn more about these kits, visit our PD product web page or contact your local Merit Sales Representative.

Lynette Ruppel
Senior Product Manager

The Importance of Having Options for Foreign Body Manipulation and Retrieval

A survey conducted by Merit Medical found that radiologists, cardiologists, and vascular surgeons use, on average, two or more different endovascular snare devices in their practice. These physicians understand the importance of having options when a foreign object such as an IVC filter, stent, balloon fragment, broken catheter tip, or guide wire tip needs to be retrieved from the vasculature.


Merit Medical recognizes this need and is pleased to be the only provider of two snare systems: an interlaced triple loop device–the EN Snare® Endovascular Snare System, and a single loop snare device–the ONE Snare® Endovascular Snare System. The EN Snare® and the ONE Snare® go hand-in-hand to provide physicians with the necessary options they need to meet any clinically-challenging case that may arise.

Check out our website to learn more about the suite of Merit Endovascular Snare Systems.

Jesse Hansen
Director of Marketing – Interventional Radiology

Retrospective Analysis Study Shows CentrosFLO® Long-Term Hemodialysis Catheter Tip Design Offers Greater Patency


The Merit Medical CentrosFLO long-term hemodialysis catheter’s self-centering split-tip design has a greater separation between the arterial and venous tips than the symmetric-tip designed catheter. Its design is intended to optimize catheter patency and reduce fibrin sheath formation, thrombosis and vessel wall occlusions by keeping the tips of the catheter centered in the vessel and away from the vessel wall.

In May of 2013, a retrospective study was completed by Dr. Saravanan Balamuthusamy (“Dr. Bala”) at Angiocare, Vascular and Interventional Nephrology, in Tucson, Arizona. The performance and safety of a new self-centering, split tip hemodialysis tunneled catheter was compared with a symmetric-tip catheter in 58 patients.

Study Conclusion1
The study results indicated that the CentrosFLO self-centering, split-tip catheter had statistically greater patency after 3 months with similar clearance and blood flow.

Split-Tip Design
(n = 38)
(n = 20)
Patency94.7%75.0%P = 0.04
Mean Clearance (Kt/V)21.4831.423NSD4 (p = 0.48)
Mean Blood Flow (ml/min)2393.93381.63NSD4 (p = 0.27)

1 Study data on file.
2 Mean value during the three-month follow-up period.
3 Mean clearance and mean blood flow did not include data from patients with no catheter patency.
4 NSD = Not Statistically Significant, p > 0.05 (t-tests).

For a full published version of this study, contact your local Merit Sales Representative.

Nate Smith – Senior Product Manager
Merit Medical Systems, Inc.